Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial
Eat slowly-GLP-1 peaks 30-60 minutes post-ingestion
"And so what we've learned over the years is that hitting the system in more than one place can often bring additive weight loss." While losing a large amount of weight may be the goal for some people, for others, it is not, which is why it's important that multiple drugs are available, according to Aronne
The medication manages a chronic condition, and discontinuation often leads to recurrence
By application, the obesity management segment is projected to grow at the fastest CAGR during the forecast period
Handle with appropriate PPE (gloves, lab coat, safety goggles)